Skip to main content

Table 4 Summary of AEs and SAEs (Safety Population)

From: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

  Lumiracoxib 100 mg o.d. (n = 755) Lumiracoxib 100 mg b.i.d. (n = 1,519) Celecoxib 200 mg o.d. (n = 758)
Patients with AEs, n (%) 548 (72.6) 1078 (71.0) 526 (69.4)
Patients with SAEs, n (%) 41 (5.4) 72 (4.7) 48 (6.3)
   Fatal, n (%) 2 (0.3) 7 (0.5) 1 (0.1)
Discontinuations due to AEs, n (%) 98 (13.0) 193 (12.7) 87 (11.5)
  1. o.d. = once daily; b.i.d. = twice daily; AEs = adverse events; SAEs = serious adverse events; all deaths occurring before database lock are included.